comprehensive -WSS

comprehensive

author：explore 2025-09-29 20:53:18 - browse：61

Several amyloid plaques forming between neurons in a brain — Adobe

Expert advisers to the Food and Drug Administration on Friday voted unanimously in favor of expanding the approval of Leqembi, an Alzheimer’s disease treatment from Eisai and Biogen, further clearing the way for what could be the first widely available medicine that delays the disease’s progress.

The group voted 6-0 that an 1,800-patient study of Leqembi confirmed its benefits for patients in the early stages of Alzheimer’s, recommending the FDA widen the drug’s limited approval. The agency, which is not required to follow the suggestions of its advisers, is expected to make a final decision on Leqembi by July 6.

“I thought the clinical results were robust,” said Merit Cudkowicz, a neurologist from Massachusetts General Hospital and one of the experts invited to review Leqembi.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： In age of alternative facts, a scholarly course on calling out crap
Next article： Neurocrine congenital adrenal hyperplasia trial succeeds

explore

WSS

CVS Caremark has created a new ploy: the drug ‘rebate credit’

Orchard's therapy for neuron disease in children wins FDA approval

CVS Caremark has created a new ploy: the drug ‘rebate credit’

CVS Caremark has created a new ploy: the drug ‘rebate credit’

Free Covid tests will again be offered to all U.S. households

Medicare to pay more for cardiac rehab in hospital outpatient clinics

hotspot

comprehensive

Wikipedia

Anesthesiologist group: stop taking Ozempic before surgery

Methadone treatment changes are coming. Do they go far enough?

How one medical school became remarkably diverse

Virtual Event: March of the Biosimilars

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

Senate bill would ban some hospital facility fees

Medical records are filled with copy

Readout Newsletter: Geron, Novo Nordisk, WuXi updates

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

Nurses recount patients attacks

focus

Akili changes sales model for its ADHD video game treatment

Fed up with FDA, ALS advocates consider a take

What happened to the House vote on health price transparency?

I was wrong about Geron's blood cancer drug. Now, is it a takeover target?

Transgender sports debate: Physicians say bans are health issue

Senate bill would ban some hospital facility fees

explore

hotspot

knowledge

focus